Ripretinib: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Ripretinib, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
Item
Content
New predicted indications
None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug
1
Evidence level
Not applicable
Australia Market Status
Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items
1 (valid: 1)
Known uses recorded for this drug
Approved (supported by a licence or label)
Indication
Source
gastrointestinal stromal tumors
licence in another country
Related to an approved indication (same disease category)
Indication
Approved category
none
none
Relations recorded in the knowledge graph (no approval found)
Indication
none
Australia Market Information
Licence
Product
Dosage form
Status
12764T
Qinlock
Tablet 50 mg
Valid
Cytotoxicity
Item
Content
Cytotoxicity Classification
Targeted therapy (tyrosine kinase inhibitor)
Myelosuppression Risk
Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification
Please refer to the Product Information (PI) warnings and precautions
Monitoring Items
Please refer to the Product Information (PI) warnings and precautions
Handling Protection
Please refer to the Product Information (PI) warnings and precautions, and local cytotoxic drug handling policy
Safety Considerations
Label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Drug Interactions: The interaction screen identified 90 potential interactions. Those flagged as Major among the first 20 entries reviewed are:
Clarithromycin
Cobicistat
Moderate-level interactions include pioglitazone, aprepitant, dexamethasone, canagliflozin, cimetidine, eliglustat, metreleptin, miconazole, repaglinide, clotrimazole, fidaxomicin, glycerol phenylbutyrate, rolapitant, rosiglitazone, troglitazone, deferasirox, fostamatinib and selexipag. Pharmacokinetic studies in the literature (verapamil in rats, and a physiologically-based pharmacokinetic model) also indicate that CYP3A4 and P-glycoprotein modulators can alter ripretinib exposure.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.